Los puntos clave no están disponibles para este artículo en este momento.
These findings document that DFU imposes substantial burden on public and private payers, ranging from 9-13 billion in addition to the costs associated with diabetes itself.
Rice et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: